feed,title,long_url,short_url
Benzinga,"Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy",https://www.benzinga.com/pressreleases/21/01/n19115787/mind-cure-signs-loi-to-acquire-an-ownership-interest-in-psychedelic-treatment-center-atma-selected,https://j.mp/2LqazxZ
Benzinga,NEXE Launches XOMA Superfoods,https://www.benzinga.com/pressreleases/21/01/n19115786/nexe-launches-xoma-superfoods,https://j.mp/3oCtO5Y
Benzinga,"Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy",https://www.benzinga.com/pressreleases/21/01/n19115785/mind-cure-signs-loi-to-acquire-an-ownership-interest-in-psychedelic-treatment-center-atma-selected,https://j.mp/35yiZdI
Benzinga,Pomerantz Law Firm Announces the Filing of a Class Action against Restaurant Brands International Inc. and Certain Officers - QSR,https://www.benzinga.com/pressreleases/21/01/n19115784/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-restaurant-brands-international-,https://j.mp/3bxGgjQ
Benzinga,NEXE Launches XOMA Superfoods,https://www.benzinga.com/pressreleases/21/01/n19115783/nexe-launches-xoma-superfoods,https://j.mp/38Ay0O0
Benzinga,Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities,https://www.benzinga.com/pressreleases/21/01/g19115782/helsinn-announces-first-patient-dosed-in-phase-12-study-of-tas0953hm06-in-patients-with-advanced-s,https://j.mp/35AKjYS
Benzinga,Central government deficit of SEK 221 billion in 2020,https://www.benzinga.com/pressreleases/21/01/tr19115781/central-government-deficit-of-sek-221-billion-in-2020,https://j.mp/2K7eb7D
Benzinga,Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities,https://www.benzinga.com/pressreleases/21/01/tr19115780/helsinn-announces-first-patient-dosed-in-phase-12-study-of-tas0953hm06-in-patients-with-advanced-,https://j.mp/3oBsqk9
